natgillin/translations-raw huggingface dataset:
Through 360 weeks of treatment, genotypic analysis of viral isolates was successfully conducted in 19 of 28 patients with confirmed HIV RNA above 400 copies/ml revealed no primary or active site mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82, 84 and 90) or protease inhibitor phenotypic resistance
Med 360 tedni zdravljenja je bila genotipska analiza virusnih izolatov uspešno izvedena pri 19 od 28 bolnikih s potrjenim HIV RNA nad 400 kopij/ml in ni pokazala nobenih primarnih mutacij ali mutacij aktivnega mesta v proteazi (aminokisline na položajih 8, 30, 32, 46, 47, 48, 50, 82, 84 in 90) ali fenotipske odpornosti proti zaviralcem proteaze.
through 9.6 years in men (n=918), 16-26 years of age at time of vaccination (median follow- up of 8.5 years); and through 8.4 years in women (n=684), 24-45 years of age at time of vaccination (median follow-up of 7.2 years).
v obdobju 9,6 leta pri moških (n = 918), ob cepljenju starih od 16 do 26 let (mediani čas spremljanja 8,5 leta) in v obdobju 8,4 leta pri ženskah (n = 684), ob cepljenju starih od 24 do 45 let (mediani čas spremljanja 7,2 leta).
Through 96 weeks in SPRING-2 and FLAMINGO and 144 weeks in SINGLE, no cases of treatment emergent primary resistance to the integrase- or NRTI-class were seen in the dolutegravir-containing arms.
V skupini, v kateri je zdravljenje obsegalo dolutegravir, niso opazili med zdravljenjem nastale primarne odpornosti proti skupini integraz ali NRTI, in sicer v študijah SPRING-2 in FLAMINGO do 96 tednov in v študiji SINGLE do 144 tednov zdravljenja.
through a plastic tube placed in your vein (intravenous infusion) usually over 90 minutes
po plastični cevki, nameščeni v veno (intravenska infuzija), običajno v času 90 minut.
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestation in the litter up to seven weeks of age.
Z mesečnim tretiranjem brejih in doječih živali močno zmanjšamo populacijo bolh, obenem pa zaščitimo leglo z mladički pred infestacijo z bolhami do njihovega sedmega tedna starosti.
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.
Z zmanjševanjem populacije bolh, mesečno zdravljenje brejih in doječih psic omogoča preprečevanje infestacije z bolhami pri mladičih.do sedmega tedna starosti.
Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of age.
Mesečno zdravljenje brejih in doječih živali zmanjša populacijo bolh in pomaga preprečiti infestacijo legla do sedmega tedna starosti.
Through a series of multiple stepwise regression analyses of baseline and on-treatment genotypes from all clinical studies, 16 amino acids have been associated with reduced tipranavir susceptibility and/or reduced 48-week viral load response: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D and 84V. Clinical isolates that exhibited a  10-fold decrease in tipranavir susceptibility harboured 8 or more tipranavir-associated mutations.
Z nizom stopenjskih regresijskih analiz izhodiščnih genotipov in genotipov med zdravljenjem v vseh kliničnih raziskavah so z zmanjšano občutljivostjo za tipranavir ali zmanjšanim 48-tedenskim odzivom virusnega bremena povezali 16 aminokislin: 10V, 13V, 20M/R/V, 33F, 35G, 36I, 43T, 46L, 47V, 54A/M/V, 58E, 69K, 74P, 82L/T, 83D in 84V. Klinični izolati z  10-krat zmanjšano občutljivostjo za tipranavir so imeli 8 ali več s tipranavirjem povezanih mutacij.
Through approximately 2 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.
Priporočilo glede periodičnih pregledov kože, predvsem za bolnike z dejavniki tveganja za kožnega raka.
Through approximately 2 years of follow-up, the incidence of non-lymphoma malignancies (excluding non-melanoma skin cancer) was similar to the general population.
V približno 4 letih spremljanja je bila incidenca nelimfomskih malignih bolezni (z izjemo nemelanomskega kožnega raka) podobna kot v splošni populaciji.
Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III.
Prek tega mehanizma fenofibrat pospeši lipolizo in odstranjevanje delcev, bogatih s trigliceridi, iz plazme, tako da aktivira lipoproteinsko lipazo in zmanjša produkcijo apoproteina C-III.
Through week 24 0.40d 0.0016 NA
(-1,4, 13,5)
Through week 24 8.1 <0.0001 6.1 (4.7, 11.4) (-1.4, 13.5)
Obdobje do 24. tedna
Through week 24, two patients who switched to Eviplera at baseline (2 of 317 patients, 0.6%) and one patient who maintained their ritonavir-boosted protease inhibitor-based regimen [Stayed on Baseline Regimen (SBR) arm] (1 of 159 patients, 0.6%) developed genotypic and/or phenotypic resistance to study drugs.
Do konca 24. tedna se je pri dveh bolnikih, ki sta na začetku prešla na zdravilo Eviplera (2 od 317 bolnikov, 0,6 %), in pri enem bolniku, ki je ohranil režim zdravljenja z zaviralcem proteaze, okrepljenim z ritonavirjem (krak z ohranitvijo začetnega režima) (1 od 159 bolnikov, 0,6 %) razvila genotipska in/ali fenotipska rezistenca na študijsko zdravilo.
Through Week 240, 3 of the 10 patients experienced virologic breakthrough (≥ 1 log10 increase above nadir).
V obdobju 240 tednov se je pri 3 od 10 bolnikov pojavilo povečanje virusnega bremena (≥ 1 log10 povečanje nad najnižjo vrednostjo).
Through week 48 0.46d 0.0012 NA
Obdobje do 48. tedna
through week 54
obdobju do 54. tedna
through week 54
v obdobju do 54. tedna
Through week 8
0,0004
Through week 8
V 24. tednu
Through week 8
zelo pogosti
Through Week 96, the development of one or more primary emtricitabine, tenofovir alafenamide, or elvitegravir resistance-associated mutations was observed in HIV-1 isolates from 10 of 19 patients with evaluable genotypic data from paired baseline and E/C/F/TAF treatment-failure isolates (10 of 866 patients [1.2%]) compared with 8 of 16 treatment- failure isolates from patients in the E/C/F/TDF group (8 of 867 patients [0.9%]).
Do vključno 96. tedna so opazili razvoj ene ali več primarnih mutacij, povezanih z rezistenco na emtricitabin, alafenamidtenofovirat ali elvitegravir, pri izolatih HIV-1 pri 10 od 19 bolnikov, pri katerih je bilo mogoče oceniti genotipske podatke parov izolatov ob začetku in izolatov neuspešnega zdravljenja z zdravilom E/C/F/TAF (10 od 866 bolnikov [1,2 %]) v primerjavi z 8 od 16 izolatov neuspešnega zdravljenja pri bolnikih v skupini z E/C/F/TDF (8 od 867 bolnikov [0,9 %]).
Throughout your treatment, the doctor will check you for any signs of bleeding. if you have been treated before with medicines similar to Angiox (e.g. lepirudin). before the start of the injection or infusion, the doctor will tell you about the signs of allergic reaction.
V času celotnega zdravljenja bo vaš zdravnik preverjal kakršnekoli znake krvavenja. če ste se v preteklosti zdravili z zdravili, podobnimi zdravilu Angiox (npr. lepirudin) pred začetkom injiciranja ali infuzije vam bo zdravnik razložil znake alergijske reakcije.
Throw away all other used items into your regular household waste.
Zavrzite vse ostale enote zdravila v običajen koš za odpadke.
Throw away any Bydureon pen that has been frozen.
Zavrzite vsak peresnik zdravila Bydureon, ki je bil zamrznjen.
Throw away any Byetta pen that has been frozen.
Injekcijski peresnik Byetta, ki je bil zamrznjen, zavrzite.
Throw away any pen that is kept out of the fridge for more than 30 days.
Vsak peresnik, shranjeno zunaj hladilnika več kot 30 dni, zavrzite.
Throw away any remaining solution.
Preostalo raztopino zavrzite.
Throw away any syringe that is kept out of the fridge for more than 30 days.
Vsako brizgo, shranjeno zunaj hladilnika več kot 30 dni, zavrzite.
Throw away any unused containers one week after opening the foil wrapper-even if the containers are still sealed.
Vse neporabljene vsebnike zavrzite en teden po odprtju folijske vrečke, tudi če so še vedno zaprti.
Throw away any unused liquid left in the first bowl.
Neuporabljeno suspenzijo zdravila Ebilfumin iz prve posode zavrzite.
Throw away any unused product in the vial and the disposable supplies as recommended by your healthcare professional.
Neuporabljeno zdravilo v viali ter pripomočke za enkratno uporabo zavrzite po navodilu zdravstvenega delavca.
Throw away needles in a puncture-resistant container or as recommended by your healthcare professional.
Igle zavrzite v embalažo, odporno proti vbodom, ali po navodilih vašega zdravstvenega delavca.
Throw away pen and cap into a puncture-resistant container immediately after use.
Peresnik in pokrovček takoj po uporabi zavrzite v vsebnik za ostre odpadke.
Throw away syringe and cap into a puncture-resistant container immediately after use.
Brizgo in pokrovček takoj po uporabi zavrzite v vsebnik za ostre odpadke.
Throw away the container and any leftover solution at once.
Takoj po uporabi zavrzite vsebnik in morebitno preostalo raztopino.
Throw away the needle as you have been instructed by your doctor or nurse
Zavrzite iglo, kot vam je naročil vaš zdravnik ali medicinska sestra.
Throw away the needle(s) into the sharps container.
Iglo(e) odvrzite v posodo za ostre predmete.
Throw away the needle-cap in the puncture resistant container or sharps container.
Odvrzite pokrovček injekcijske igle v zabojnik za ostre predmete, odporen proti vbodom.
Throw away the packaging box, inner needle cap, peel tab, alcohol swab and the instructions for use in the household waste.
Zunanjo škatlo, notranji ščitnik igle, jeziček, alkoholni zloženec in navodila za uporabo zavrzite v gospodinjske odpadke.
Throw away the Pen you are using after 28 days, even if it still has insulin left in it.
Peresnik, ki ga uporabljate, zavrzite po 28 dneh, tudi če je v njem še insulin.
Throw away the pen you are using after 28 days, even if it still has insulin left in it.
Zavrzite peresnik, ki ga uporabljate, po 28 dneh, tudi če je v njem še insulin.
Throw away the Pen you are using after the time specified in the Package Leaflet, even if it still has insulin left in it.
Peresnik, ki ga uporabljate, zavrzite po času, ki je za to naveden v Navodilu za uporabo, tudi če je v njem še insulin.
Throw away the unused needle with the outer needle cap still on.
Zavrzite neuporabljeno iglo z nameščenim zunanjim pokrovčkom.
Throw away the used needle in a puncture resistant container, or as told by your pharmacist or local authority.
Uporabljene igle zavrzite v vsebnik, odporen proti prebadanju, ali kot vam naroči farmacevt ali pristojni lokalni organ.
Throw away the used Plegridy pen into a special secure container, such as a sharps bin.
Uporabljen injekcijski peresnik zdravila Plegridy zavrzite v posebni varnostni vsebnik, na primer koš za ostre odpadke.
Throw away the used Plegridy pre-filled syringe into a special secure container, such as a sharps bin.
Uporabljeno injekcijsko brizgo zdravila Plegridy zavrzite v posebni varnostni vsebnik, na primer koš za ostre odpadke.
Throw away the vials, used syringes and needles in the puncture- resistant container.
Zavrzite viale, uporabljene brizge in igle v vsebnik za ostre odpadke.
Throw away used needles in a puncture-resistant container or as recommended by your healthcare professional.
Uporabljene igle zavrzite v embalažo, odporno proti vbodom, ali po navodilih vašega zdravstvenega delavca.
Throw away used syringes in a puncture-resistant container or sharps container.
Uporabljene injekcijske brizge zavrzite v zabojnik za oste predmete, odporen proti vbodom.
Throw away used syringes in a sharps/ puncture-resistant container.
Odvrzite uporabljene injekcijske brizge v vsebnik za odpadni material, ki je odporen proti vbodom.
Throw away your Lyxumia pen, ask your pharmacist how to throw away medicines you no longer use.
Peresnik Lyxumia zavrzite, s farmacevtom se posvetujte o načinu odstranjevanja zdravil, ki jih ne potrebujete več.
Throw away your used pen as told by your pharmacist or local authority.
Uporabljeni peresnik zavrzite, kot vam naroči farmacevt ali pristojni lokalni organ.
Throw the needles away after each use.
Igle po vsaki uporabi zavrzite.
Throw the pen away and use a new one.
Zavrzite ta injekcijski peresnik in uporabite novega.
Throw the pre-filled pen away (see figure 10)
Napolnjeni injekcijski peresnik zavrzite (glejte sliko 10)
Throw the swab away.
Blazinico zavrzite.
Throw the wipe away.
Blazinico zavrzite.
Throw this sachet away don’t eat or inhale it.
To vrečko zavrzite – ne smete je zaužiti ali vdihniti (inhalirati).
Throw this sachet away – do not eat or inhale it.
To vrečko zavrzite – ne smete je zaužiti ali vdihniti (inhalirati).
Throw this sachet away – don’t eat or inhale it.
To vrečko zavrzite – ne smete je zaužiti ali vdihniti (inhalirati).
Throwing away leftover medicine
Odstranjevanje preostalega zdravila
Throwing away supplies
Odstranjevanje odpadkov
throwing up
bruhanje,
Throwing up (vomiting)
bruhanje,
thrush or genital yeast infection
ustni oprh ali glivična okužba spolovil
Thumb pad
Blazinica za palec
Thus dogs with sociopathic disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific (dog to another species) aggressions should not be castrated either surgically or with the implant.
Zato psov s sociopatskimi motnjami ali z epizodami intra-specifičnih (psa na psa) in/ali inter-specifičnih (psa na drugo vrsto) agresij ni priporočljivo kastrirati tako kirurško kot z implantatom.
Thus for initiation of the therapy on the first day, twice the maintenance volume will be required.
V prvem dnevu zdravljenja je torej potreben dvakratni volumen vzdrževalnega odmerka.
Thus for initiation of the treatment of chronic musculo- skeletal disorders on the first day, twice the maintenance volume will be required.
Prvi dan zdravljenja kroničnih mišično-skeletnih obolenj je torej potreben dvakratni volumen vzdrževalnega odmerka.
Thus it may take a day or two before you or your child is off INOmax therapy.
Zato bo pri vas ali vašem otroku odvajanje od zdravljenja z zdravilom INOmax morda trajalo dan ali dva.
Thus moderate inhibitors of CYP2C19 are unlikely to affect systemic lacosamide exposure to a clinically relevant extent.
Glede na to zmerni zaviralci CYP2C19 malo verjetno vplivajo na sistemsko izpostavljenost lakozamida do klinično pomembnega obsega.
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and
Zato ni pričakovati kakega posebnega medsebojnega delovanja, kar je bilo potrjeno s študijami in vivo, kjer niso opazili nobenega zaviranja presnove naslednjih učinkovin: tricikličnih antidepresivov (ki predstavljajo predvsem pot CYP2D6), varfarina (CYP2C9), teofilina (CYP1A2) ali diazepama (CYP3A4 in 2C19).
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and CYP2C19).
Zato ni pričakovati kakega posebnega medsebojnega delovanja, kar je bilo potrjeno s študijami in vivo, kjer niso opazili nobenega zaviranja presnove naslednjih učinkovin: tricikličnih antidepresivov (ki predstavljajo predvsem pot CYP2D6), varfarina (CYP2C9), teofilina (CYP1A2) ali diazepama (CYP3A4 in 2C19).
Thus the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.
Ti podatki kažejo, da glukuronidacija z UGT1A1 pri človeku predstavlja glavni mehanizem očistka raltegravirja.
Thus the data on a limited number of exposed pregnancies indicate no adverse effects on pregnancy or on the health of the foetus/newborn.
Tako podatki na majhnem številu izpostavljenih nosečnosti ne kažejo nobenih neželenih učinkov na nosečnost ali zdravje zarodka/novorojenčka,
Thus the radiation equilibrium between measuring and comparative beam is disturbed.
S tem je ravnovesje žarčenja med merilnim in kontrolnim žarkom porušeno.
Thus trifluridine is not expected to cause or be subject to a significant medicinal product interaction mediated by CYP.
Zato naj trifluridin ne bi bil vključen v pomembno medsebojno delovanje z drugimi zdravili prek CYP.
Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance.
Zato 5 ml rekonstituirane raztopine ustreza 50 mg zdravilne učinkovine.
Thus, Abilify Maintena is unlikely to cause clinically important medicinal product interactions mediated by these enzymes.
Zato ni verjetno, da bi zdravilo Abilify Maintena povzročilo klinično pomembno medsebojno delovanje prek teh encimov.
Thus, anti-inflammatory treatments, such as with the IL-17A inhibitor ixekizumab, may result in normalisation of CYP450 levels with accompanying lower exposure of CYP450-metabolised co- medications.
Zato lahko protivnetna zdravila, kot je iksekizumab, ki je zaviralec IL-17A, povzročijo normaliziranje ravni CYP450, skupaj s spremljajočo nižjo izpostavljenostjo sočasno danih zdravil, ki se presnavljajo prek CYP450.
Thus, anti-inflammatory treatments, such as with the IL-17A inhibitor secukinumab, may result in normalisation of CYP450 levels with accompanying lower exposure of CYP450-metabolised co-medications.
Tako bi protivnetna zdravila, kot je sekukinumab, ki je zaviralec IL-17A, lahko povzročila normalizacijo koncentracije encimov CYP450 in zmanjšala izpostavljenost sočasnim zdravilom, ki se presnavljajo z encimi CYP450.
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4).
3 mesece opažena korist v skupini, ki je prejemala klopidogrel in ASA, ni nadalje povečevala, medtem ko je tveganje za krvavitev ostala (glejte poglavje 4.4).
Thus, Brilique 90 mg twice daily together with low-dose ASA can be used in patients with ACS (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Zdravilo Brilique 90 mg dvakrat na dan je torej mogoče uporabljati skupaj z nizkoodmerno ASA pri bolnikih z AKS (nestabilno angino pektoris, miokardnim infarktom brez dviga ST [NSTEMI] ali z dvigom ST [STEMI]), vključno s konzervativno zdravljenimi bolniki in bolniki, zdravljenimi s perkutano koronarno intervencijo (PKI) ali obvodno koronarno operacijo.
Thus, caution should be exercised in patients with impaired cardiac function.
Zato morate biti pri bolnicah z okvarjenim delovanjem srca previdni.
Thus, changes in blood protein levels in various disease states (e.g., renal or hepatic impairment) are not expected to alter the disposition of saxagliptin.
Zato ni pričakovati, da bi spremembe v koncentraciji beljakovin v krvi pri različnih bolezenskih stanjih (npr. okvari ledvic ali jeter) spremenile odstranjevanje saksagliptina.
Thus, CHMP decided that Imlygic’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor je zato zaključil, da so koristi zdravila Imlygic večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Thus, clinically significant interactions mediated through inhibition of cytochrome P450 system by rufinamide are unlikely to occur.
Zato ni verjetno, da bi nastopile klinično pomembne interakcije, ki bi jih posredovalo zaviranje sistema citokroma P450 z rufinamidom.
Thus, concurrent administration of antithrombin with heparin, low molecular weight heparin, or other anticoagulants that potentiate the anticoagulant activity of antithrombin to a patient with increased risk of bleeding must be monitored clinically and biologically.
Zato je treba hkratno uporabo antitrombina s heparinom, heparinom z nizko molekularno maso ali drugimi antikoagulanti, ki okrepijo antikoagulantno aktivnost antitrombina, pri bolnikih s povečano nevarnostjo krvavenja nadzorovati klinično in biološko.
Thus, data are not available to recommend a lower starting dose in patients with hepatic impairment.
Zato ni na voljo podatkov o priporočenem nižjem začetnem odmerku pri bolnikih z motenim delovanjem jeter.
Thus, decitabine exposure is not likely to be affected in patients with impaired hepatic function.
Okvara jeter torej verjetno ne vpliva na izpostavljenost decitabinu.
Thus, decitabine exposure is not likely to be affected in patients with impaired renal function.
Okvara ledvic torej verjetno ne vpliva na izpostavljenost decitabinu.
Thus, dimethylsulfoxide (DMSO) should not be used in patients who are administered dexrazoxane to treat anthracycline extravasation.
Zato se dimetilsulfoksid (DMSO) ne sme uporabiti pri bolnikih, ki za zdravljenje antraciklinske ekstravazacije prejemajo deksrazoksan .
Thus, dogs with sociopathic disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific (dog to another species) aggressions should not be castrated either surgically or with the implant.
Zato psov s sociopatskimi motnjami ali z epizodami intra-specifičnih (psa na psa) in/ali inter-specifičnih (psa na drugo vrsto) agresij ni dovoljeno kastrirati tako kirurško kot z implantatom.
Thus, dogs with sociopathic disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific (dog to another species) aggressions should not be castrated either surgically or with the implant.
Zato psov s sociopatskimi motnjami ali z epizodami intra-specifičnih (psa na psa) in/ali inter-specifičnih (psa na drugo vrsto) agresij ni priporočljivo kastrirati tako kirurško kot z implantatom.
Thus, during treatment or at the end of treatment at the latest, an appropriate feeding and exercise regimen should be implemented in order to ensure long term maintenance of the bodyweight.
Med zdravljenjem ali ob koncu le-te je potrebno določiti pravilen način prehrane in gibanja, da se zagotovi dolgoročno ohranjanje telesne mase.
Thus, each 2 ml of reconstituted solution contains 40 mg of parecoxib.
Tako 2 ml pripravljene raztopine vsebuje 40 mg parekoksiba.
Thus, each 2 ml of reconstituted solution provides 40 mg of parecoxib
Tako 2 ml pripravljene raztopine vsebuje 40 mg parekoksiba.
Thus, each 2 ml of reconstituted solution provides 40 mg of parecoxib.
Tako 2 ml pripravljene raztopine vsebuje 40 mg parekoksiba.
Thus, entacapone should be administered cautiously to patients being treated with medicinal products metabolised by catechol-O- methyl transferase (COMT), e.g. rimiterole, isoprenaline, adrenaline, noradrenaline, dopamine, dobutamine, alpha-methyldopa, and apomorphine (see also section 4.5).
Zato je potrebna previdnost pri predpisovanju entakapona bolnikom, zdravljenim z zdravili, ki jih presnavlja katehol-O-metiltransferaza (COMT), npr. z rimiterolom, izoprenalinom, adrenalinom, noradrenalinom, dopaminom, dobutaminom, alfametildopo in apomorfinom (glejte tudi poglavje 4.5).
Thus, for these medicinal products, results and dosing recommendations of the Viekirax and dasabuvir regimen can be extrapolated to Viekirax without dasabuvir.
Za ta zdravila je torej mogoče rezultate in priporočila za odmerjanje pri shemi z zdravilom Viekirax in dasabuvirjem ekstrapolirati na shemo z zdravilom Viekirax brez dasabuvirja.
Thus, in a patient prescribed any dose of tadalafil (2.5 mg-20 mg), where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of tadalafil before nitrate administration is considered.
Zato naj pri bolniku, ki ima predpisan katerikoli odmerek zdravila Tadalafil Mylan (2,5 mg-20 mg) in kjer je dajanje nitrata zdravstveno nujno v življenje ogrožajoči situaciji, pred dajanjem nitrata preteče vsaj 48 ur po zadnjem odmerku zdravila Tadalafil Mylan.